Xianhui Meng - Sihuan Pharmaceutical Director
Director
Mr. Meng Xianhui is Deputy General Manager of Sihuan Pharmaceutical Holdings Group Ltd. He was appointed to our Board on 18 May 2006. He joined our Group in 2002 and is responsible for public and governmental relationships as well as operations of the sales and marketing network of our Group in certain regions. Prior to joining our Group, Mr. Meng had more than 7 years of experience in the pharmaceutical industry in the areas of marketing, sales and distribution of pharmaceutical products. Between 1987 and 1997, Mr. Meng was the departmental head of Jilin Materials Bureau where he was responsible for planning the allocation and distribution of production materials. Mr. Meng was conferred the title of Economist by the Jilin Provincial Government in 1993. Mr. Meng received a Graduate Certificate in Management Engineering from Huazhong Engineering College in 1987. He undertook a oneyear Postgraduate Business Administration course at the Peking University from 2004 to 2005. since 2017.
| Age | 59 |
| Tenure | 8 years |
| Phone | 852 3628 3911 |
| Web | https://www.sihuanpharm.com |
Sihuan Pharmaceutical Management Efficiency
Sihuan Pharmaceutical's management efficiency ratios could be used to measure how well Sihuan Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Sihuan Pharmaceutical Holdings has accumulated 844.75 M in total debt with debt to equity ratio (D/E) of 0.14, which may suggest the company is not taking enough advantage from borrowing. Sihuan Pharmaceutical has a current ratio of 2.38, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Sihuan Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Sihuan Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sihuan Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sihuan to invest in growth at high rates of return. When we think about Sihuan Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 9 records | DIRECTOR Age | ||
| Frank Fallwell | SNDL Inc | N/A | |
| Norma Beauchamp | Aurora Cannabis | 59 | |
| Daniel JD | Phibro Animal Health | 53 | |
| Margaret Atkins | Aurora Cannabis | 63 | |
| Jason Dyck | Aurora Cannabis | N/A | |
| Adam Szweras | Aurora Cannabis | 48 | |
| Tyler Burns | Canopy Growth Corp | N/A | |
| Max Schwartz | OrganiGram Holdings | N/A | |
| David Lazzarato | Canopy Growth Corp | 64 | |
Management Performance
| Return On Equity | -0.0487 | |||
| Return On Asset | -4.0E-4 |
Sihuan Pharmaceutical Leadership Team
Elected by the shareholders, the Sihuan Pharmaceutical's board of directors comprises two types of representatives: Sihuan Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sihuan. The board's role is to monitor Sihuan Pharmaceutical's management team and ensure that shareholders' interests are well served. Sihuan Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sihuan Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Weicheng Guo, Deputy Chairman, CEO and Member of Nomination Committee | ||
| Xianhui Meng, Deputy General Manager of Sales and Marketing and Executive Director | ||
| Yanling Chen, Joint Director | ||
| Guili Miao, Chief CEO | ||
| Kin Li, Joint Sec | ||
| Fengsheng Che, Co-Founder, Executive Chairman and Member of Remuneration Committee | ||
| Jionglong Zhang, Non-Executive Director | ||
| Chengkon Shih, General Manager of Shandong Xuanzhu | ||
| Feng Guo, Executive Director |
Sihuan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sihuan Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0487 | |||
| Return On Asset | -4.0E-4 | |||
| Profit Margin | (0.05) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 506.36 M | |||
| Shares Outstanding | 9.33 B | |||
| Shares Owned By Insiders | 55.02 % | |||
| Shares Owned By Institutions | 4.21 % | |||
| Price To Earning | 8.75 X | |||
| Price To Book | 0.81 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Sihuan Pink Sheet
If you are still planning to invest in Sihuan Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sihuan Pharmaceutical's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |